admission date:  [2103-8-7]              discharge date:   [2103-9-23]date of birth:  [2056-3-4]             sex:   fservice: medicineallergies:compazineattending:[first name3 (lf) 3913]chief complaint:hypercalcemiamajor surgical or invasive procedure:nonehistory of present illness:ms. [known lastname 4003] is a 47 year old woman who carries a diagnosis ofhtlv-associated adult t-cell leukemia/lymphoma who presents fromroutine clinic appointment with hypercalcemia, with a correctedcalcium of 15.5. she received a liter of normal saline, but nobisphosphonate, and was subsequently admitted to the floor..she was recently hospitalized from [2103-7-11] through [2103-8-4], alsofor hypercalcemia with acute mental status changes, which wasattributed to progression of her hematologic malignancy.following iv hydration and zometa, her calcium normalized, andshe underwent treatment with [hospital1 ] cycle 1. her post-chemocourse was unfortunately complicated by dic requiring multiplecryoprecipitate, c. dif colitis, cmv viremia, and a severeabdominal pain requiring bowel rest with tpn. she developed alll pnuemonia towards the end of her hospitalization and wasdischarged on a 10 day course of levaquin in addition to hometpn..since her discharge, ms. [known lastname 4003] has been slowly regaining herstrength, noting persistent fatigue which has acutely worsenedtoday. she denies acute confusion or mental status changes whichaccompanied her previous hypercalcemic episode. she notes nopain or paresthesias or tetany. her last hospitalization wascomplicated by severe abdominal pain requiring bowel rest- sheremains on home tpn and has been tolerating light meals due to asense of fullness. she also had cxr evidence of lll pneumoniaand had been discharged on levaquin, which she has taken. shehad also developed c.dif, and cmv viremia, which had beenmaintained on po flagyl x 14d and valganciclovir in theoutpatient setting..on review of systems, the patient denies fevers, chills, nausea,vomiting, diarrhea, malaise, rigors, abdominal pain, blood inthe stools, shortness of breath, cough, dysuria, hematuria,paresthesias, weakness.past medical history:stage [doctor first name ] mycosis fungoides (cutaneous t-cell lymphoma, stage iv1a) with transformation to cd-30 positive large cell lymphomaand development of htlv-1 adult t-cell leukemia lymphoma.- [10-29]: the patient developed a pruritic, papular rash. shewas seen in the internal medicine and dermatology clinics onseveral occasions and was treated with antibiotics,triamcinolone, clobetasol, and iv triamcinolone w/ noimprovement.- [2100-3-12]: skin bx 1: lle: superficial and deep perivascularlymphohistiocytic infiltrate with perivascular and interstitialeosinophils consistent with a hypersensitivity rxn. scabies neg.- [2100-7-13]: skin bx 2: atypical superficial and deep dermallymphoid infiltrate containing cd30-positive cells and showingepidermotropism. pcr analysis for the t-cell receptor gamma geneshowed two sharp bands with a migration pattern suggestive of aclonal rearrangement.- [2100-8-24]: [hospital ] clinic: wbc 10.6 with 57% lymphocytes s??????zarycells.immunophenotypic analysis -> expanded t-cell population withincreased cd4:cd8 ratio (15) and loss of cd7. due to her highcount of circulating s??????zary cells, she was felt to have stage[doctor first name 690] mycosis fungoides.- [2100-9-8] ct scan: infiltrating, hypo-enhancing lesion in ther. kidney (?infiltrating neoplasm vs pyelonephritis) compatiblew/ lymphomatous involvement of the kidney but was not present ona follow-up scan on [2101-1-21].- [9-30]: photopheresis therapy through an indwelling centralvenous catheter, placed due to poor venous access.- [2101-1-5]: skin bx 3: ctcl with large-cell transformation.- [2101-1-10]: interferon alpha at 3m units 3x/wk given w/ withphotopheresis every other week and puva.- [2101-1-26]: interferon alpha increased to 6munits 3x/wk; puva wasd/ced [12-26] side effects.- [2101-2-23]: interferon alpha decreased to 4.5munits 3x/wk on[2101-2-23] b/c fatigued. photopheresis was d/ced when catheterremoved due to a line infection (last treatment [2101-3-10]).- [2101-8-4]: the patient presented for a follow-up evaluation withclear evidence of disease progression. interferon alpha wasincreased to 6m units three times weekly and bexarotene wasstarted at 150mg daily, decreased to 75mg daily due to poortolerability.- [2101-8-25]: mtx added to interferon alpha and bexarotene and thedose was up-titrated to 45mg weekly.- [2101-10-18]: hospital admission for severe lower extremity painat the site of new, large, papular skin lesions. biopsy showedcutaneous t-cell lymphoma with large cell transformation,involving the panniculus with an unusual angiocentric pattern.the patient was prescribed vorinostat 400mg daily (started[2101-10-27]) with continuation of interferon alpha 6m units tiw. dueto thrombocytopenia, interferon alpha was decreased to 3m units3x/wk.- [2101-12-22]: cycle 1 day 1 liposomal doxorubicin plus gemcitabine.vorinostat and interferon alpha were d/ced. side effect: severepalmar-plantar erythrodysesthesia [12-26] to liposomal doxorubicin.- [2102-1-17]: cycle 1 day 1 bortezomib plus gemcitabine,dose-reduced during cycle 2 due to neutropenia.- [2102-2-9] 3m units tiw interferon alpha restarted- [2102-3-9]: due to the observation that peripheral t-cellscontained floret-like nuclei, immunophenotypic analysis wasperformed on peripheral blood, revealing findings consistentwith involvement by patient's known t cell lymphoproliferativedisorder as well as cd25 co-expression in a significantpopulation of the neoplastic cd3+ lymphocytes, suggesting adiagnosis of htlv-1 associated lymphoma. pcr for htlv-1 dna waspositive.- [2102-5-26]: following a treatment break, the patient was startedon pentostatin 4mg/m2 weekly x4 doses with reinitiation ofinterferon alpha at 3munits 3x/wkly , increased to 3munits 5x/wkly. she d/ced therapy after 2 cycles in [7-2] in favorof a chinese herbal preparation she received in [location (un) 4708].- [2102-8-18]: evaluation in the [hospital 18] [hospital 3242] clinic: good candidatefor allo sct.- [2102-9-26]: ct scan: s/p 3 mo off therapy: stable to improveddisease: lymph nodes in the chest, abdomen, and pelvis, arestable to decreased in size since [2102-7-28], with no new pathologiclad identified. decreased size of the previously enlargedspleen, now within normal limits in size.- [2102-12-25] initiation of ontak therapy cycle 1 [2102-12-25], cycle 2[2103-1-15], cycle 3 [2103-2-5], cycle 4 [2103-2-26], cycle 5[2103-6-4], cycle 6 [2103-7-2]- [2103-4-26]: 2 weeks of total skin electron beam therapy at the[hospital3 2358] under the care of dr. [first name4 (namepattern1) 3403] [last name (namepattern1) ]. therapy was held[2103-5-18] through [2103-5-24] [12-26] fatigue. she received a single doseon friday [2103-5-25].- [2103-5-29]: hypercalcemia: ivf and zometa.- [2103-5-29]: treatment discussion: re: total skin electron beamtherapy: progressive disease and difficulty tolerating therapy.decision to resume ontak therapy with intention of initiatingauto-transplant as she demonstrates response.-[2103-7-11]: admitted for ams in the setting of hypercalcemia,which was thought to be due to progression of atll. started[hospital1 ] [7-11], complicated by c dif, cmv viremia, dic.social history:the patient is from [location (un) 4708]. she moved to the u.s. 11 yearsago. she is married and has two children. she denies past orcurrent tobacco, etoh or illicit drug use.family history:mother had an mi. her father with cad.physical exam:vs: t98.9 bp128/86 p109 rr18 sa02100rageneral: fatigued appearing female in no acute distressheent: eomi, perrla, white plaques along lateral left border oftongue, pharyngeal wall nonerythematous without exudatespulmonary: minimal bibasilar crackles, otherwise clear toauscultationcards: rrr, normal s1, s2, 3/6 systolic ejection murmur. no rubsor gallops.abdomen: soft, nondistended, positive bowel sounds, mildtenderness to palpation of the ruq which is chronic, no reboundtenderness or guarding.extremities: nonedematous, 2+ pt, dp pulses bilaterallyneurologic: cn ii-xii intact bilaterally. strength 5/5throughout though deconditioned. sensation to soft touch intactthroughout. dtrs depressed.skin: no rashes or lesions appreciated.pertinent results:admission labs:.[2103-8-7] 11:30am   pt-15.1 ptt-35.9 inr(pt)-1.3[2103-8-7] 11:30am   plt count-129#[2103-8-7] 11:30am   hypochrom-1+ anisocyt-2+ poikilocy-1+macrocyt-2+ microcyt-normal polychrom-normal ovalocyt-1+[2103-8-7] 11:30am   neuts-38 bands-3 lymphs-45 monos-6 eos-0basos-0 atyps-8 metas-0 myelos-0[2103-8-7] 11:30am   wbc-16.9 rbc-2.57 hgb-8.5 hct-25.5mcv-99 mch-32.9 mchc-33.2 rdw-17.9[2103-8-7] 11:30am   albumin-2.9 calcium-14.6 phosphate-7.2#magnesium-2.2[2103-8-7] 11:30am   alt(sgpt)-14 ast(sgot)-26 alk phos-209 totbili-0.4[2103-8-7] 11:30am   glucose-103 urea n-34 creat-1.1 sodium-145potassium-3.8 chloride-105 total co2-31 anion gap-13[2103-8-7] 06:57pm urine  blood-neg nitrite-neg protein-negglucose-neg ketone-neg bilirubin-neg urobilngn-neg ph-6.5leuk-neg[2103-8-7] 06:57pm urine  color-straw appear-clear sp [last name (un) 155]-1.007[2103-8-7] 09:48pm   calcium-14.1.imaging:cxr [2103-8-12]: cardiac size is normal. et tube tip is in astandard position 3.8 cm above the carina. right picc tip is inthe mid svc. left subclavian catheter tip is in the proximalsvc. there is no pneumothorax. new bibasilar opacities, leftgreater than right, are a combination of pleural effusions andatelectasis. superimposed infection on the left cannot betotally excluded.  ng tube tip is in the stomach..head mri [2103-8-12]:findings: there is mild prominence of sulci and ventriclesinappropriate for patient's age. there is no midline shift ormass effect. there is no hydrocephalus. there is no acuteinfarct seen on diffusion images. following gadolinium, there isno abnormal parenchymal, vascular or meningeal enhancementidentified. in particular, there is no leptomeningealenhancement seen.soft tissue changes are visualized in the paranasal sinuses dueto mucosal thickening. diffuse low signal is identified withinthe bony structures,which could be secondary to marrow hyperplasia. it should benoted that onflair images, increased signal identified at the sulci at theconvexity issecondary to these images were obtained following gadolinium.impression: no acute infarcts or enhancing brain lesions areidentified. no mass effect or hydrocephalus. other findings asdescribed above..portable abdomen [2103-8-12]:ng tube tip is in the stomach. there is no evidence of bowelobstruction.nondistended air-filled large bowel loops are seen. there are nopathologic intraabdominal calcifications..ct torso: [2103-8-27]1. no evidence of pulmonary embolus or acute aortic syndrome.2. interval development of right middle upper lobe airspaceconsolidationmost consistent with pneumonia, with additional focus of opacityin the left perihilar region, possibly representing additionalfocus of infection,although enlargement of left hilar lymph nodes is difficult toexclude.followup imaging following treatment to ensure resolution isrecommended.3. splenomegaly.4. retroperitoneal adenopathy, grossly stable from [2103-6-24].5. no intra-abdominal explanation for fever. colon is diffuselyfluid-filled but thin-walled and without associated inflammatorychange. there is no loculated fluid collection or abscessidentified.6. diffuse soft tissue anasarca..bronchial embolization: [2103-9-4].impression: uncomplicated embolization of the right bronchialartery with300-500 micron embospheres until stasis was achieved..ct head [2103-9-17].no acute hemorrhagic mass seen, nor large area of edema or masseffect on non-contrast head ct. however, for evaluation ofsubtle process,mri before and after iv gadolinium would be recommended for moresensitiveevaluation..peripheral blood analysis:flow analysis:interpretationmore than 99% of the peripheral blood lymphocytes arecd4-positive subset with co-expression of cd3, cd2, cd5.  theyhave loss of expression of cd7.  about half of these t-cellsalso express cd25.  these immunophenotypic findings and thepresence of "floret-like cells" in peripheral blood smear areconsistent with involvement by patient's known "adult t cellleukemia/lymphoma"..microbiology:major studies/findings listed here:[2103-9-4] 4:49 pm bronchoalveolar lavage   gram stain (final [2103-9-4]):      no polymorphonuclear leukocytes seen.      no microorganisms seen.   respiratory culture (final [2103-9-6]):    no growth, <1000cfu/ml.   legionella culture (final [2103-9-11]):    no legionellaisolated.   potassium hydroxide preparation (final [2103-9-4]):      test cancelled by laboratory.      patient credited.      this is a low yield procedure based on our in-housestudies.      if pulmonary histoplasmosis, coccidioidomycosis,blastomycosis,      aspergillosis or mucormycosis is strongly suspected,contact the      microbiology laboratory (7-2306).   immunoflourescent test for pneumocystis jirovecii (carinii)(final      [2103-9-5]):    negative for pneumocystis jirovecii(carinii)..   fungal culture (final [2103-9-17]):    no fungus isolated.   acid fast smear (final [2103-9-5]):      no acid fast bacilli seen on concentrated smear.   acid fast culture (preliminary):    no mycobacteria isolated.   viral culture: r/o cytomegalovirus (final [2103-10-3]):      no cytomegalovirus (cmv) isolated.[2103-8-28] 1:43 pm bronchoalveolar lavage      bronchial lavage, right middle lobe.   gram stain (final [2103-8-28]):      2+   (1-5 per 1000x field):   polymorphonuclearleukocytes.      no microorganisms seen.   respiratory culture (final [2103-8-30]):    no growth, <1000cfu/ml.   potassium hydroxide preparation (final [2103-8-29]):      no fungal elements seen.      this is a low yield procedure based on our in-housestudies.      test requested by pulmonary fellow [numeric identifier 28457] [2103-8-29].   immunoflourescent test for pneumocystis jirovecii (carinii)(final      [2103-8-29]):    negative for pneumocystis jirovecii(carinii)..   fungal culture (final [2103-9-14]):      yeast.   nocardia culture (final [2103-9-17]):    no nocardia isolated.   acid fast smear (final [2103-8-29]):      no acid fast bacilli seen on concentrated smear.   acid fast culture (preliminary):    no mycobacteria isolated..[2103-8-28] 11:31 am sputum     site: expectorated      source: expectorated.                            final report [2103-9-14]   gram stain (final [2103-8-28]):      <10 pmns and <10 epithelial cells/100x field.      no microorganisms seen.      quality of specimen cannot be assessed.   respiratory culture (final [2103-8-30]):      rare growth commensal respiratory flora.      yeast.    rare growth.   fungal culture (final [2103-9-14]):      yeast..[2103-8-12] 11:24 am sputum      source: endotracheal.                            final report [2103-8-14]   gram stain (final [2103-8-12]):      <10 pmns and <10 epithelial cells/100x field.      no microorganisms seen.      quality of specimen cannot be assessed.   respiratory culture (final [2103-8-14]):      commensal respiratory flora absent.      yeast.    sparse growth..[2103-8-21] 9:31 pm urine      source: cvs.                            final report [2103-8-23]   urine culture (final [2103-8-23]):      escherichia coli.    >100,000 organisms/ml..         presumptive identification.         piperacillin/tazobactam sensitivity testing availableon request.                              sensitivities: mic expressed inmcg/ml_________________________________________________________                             escherichia coli                             |ampicillin------------     4 sampicillin/sulbactam--     4 scefazolin-------------   <=4 scefepime--------------   <=1 sceftazidime-----------   <=1 sceftriaxone-----------   <=1 sciprofloxacin---------   =>4 rgentamicin------------   <=1 smeropenem-------------<=0.25 snitrofurantoin--------  <=16 stobramycin------------   <=1 strimethoprim/sulfa----  =>16 r.test                          result              referencerange/unitsaspergillus antigen           6.5  h              <0.5.  	test----fungitell (tm) assay for (1,3)-b-d-glucansresults                                 reference ranges-------                                 ----------------358 pg/ml                               negative       less than60 pg/ml                                        indeterminate  60 - 79pg/ml                                        positive       greaterthan or equal to                                                       80 pg/mlbrief hospital course:in brief, ms. [known lastname 4003] was a 47 year old lady with a diagnosis ofhtlv-1 associated adult t cell leukemia/lymphoma who initiallypresented with hyerpcalcemia.  her hospital course wascomplicated by mental status changes which after ice therapynecessitating an admission to the icu without any acute evidenceof an intracranial process. her hospital course at this time wasalso complicated by persistent atll, hypercalcemia, renaltubular acidosis, acute renal failure, c. diff colitis, and cmvviremia.  subsequently she developed hypoxic respiratory failuresecondary to invasive aspergillosis with pulmonary hemorrhage.she underwent a pulmonary embolization procedure and a secondintubation and icu stay.  upon returning to the floor, noadditional therapeutic intervention was started for her atll.her mental status continued to deteroirate, and she stoppedtaking po.  due to disease progression in addition to apersistent fungal infection and concern for aspiration goals ofcare were discussed with her family.  due to her poor prognosis,she was made dnr/dni, and subsequently cmo.  she passedpeacefully on [2103-9-23].medications on admission:1. folic acid 1 mg tablet sig: one (1) tablet po daily (daily).2. levothyroxine 100 mcg tablet sig: one (1) tablet po daily(daily).3. valganciclovir 450 mg tablet sig: two (2) tablet po bid (2times a day). disp:60 tablet(s) refills:24. metronidazole 500 mg tablet sig: one (1) tablet po q8h (every8 hours). disp:28 tablet(s) refills:05. lorazepam 0.5 mg tablet sig: 1-2 tablets po q4h (every 4hours) as needed for nausea, anxiety.6. metoclopramide 10 mg tablet sig: 0.5 tablet po tid (3 times aday).7. doxepin 25 mg capsule sig: [11-25] capsules po once a day.8. spironolactone 25 mg tablet sig: two (2) tablet po twice aday.9. pyridoxine 100 mg tablet sig: four (4) tablet po once a day.10. fexofenadine 60 mg tablet sig: one (1) tablet po twice aday.11. allopurinol 300 mg tablet sig: one (1) tablet po once a day.12. benadryl oral13. levaquin 750 mg tablet sig: one (1) tablet po once a day for9 days. disp:9 tablet(s) refills:014. line flush order sodium chloride 5-10ml pre- and postinfusion heparin 10units/ml [12-29] ml infused as a final flush15. metoclopramide 5 mg tablet sig: one (1) tablet po threetimes a day as needed for nausea.discharge medications:nonedischarge disposition:expireddischarge diagnosis:deceased.discharge condition:nonedischarge instructions:nonefollowup instructions:nonecompleted by:[2103-10-17]